Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery, Mirna Collaborate on miRNA Mimics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mirna Therapeutics will test the effect of its proprietary miRNA mimics on a panel of Horizon Discovery's human isogenic cancer cell models, under a collaboration announced today.

Under the deal, Horizon's X-Man human discovery cell lines will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna's miRNA mimics.

The project is being funded partly by a Cancer Prevention and Research Institute of Texas commercialization grant. Other terms of the deal were not disclosed.

In a statement, Paul Lammers, president and CEO of Mirna, said the partnership will "increase the understanding of how our highly potent tumor suppressor miRNA mimics act under human cancer cells characterized by different disease-causing mutations," which in turn will help the company to better define the best patient population for clinical trials.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.